SCHEMBL20877416

SCHEMBL20877416

CC(C)(C)OC(=O)NC1CCC(C(=O)Nc2ncc(C3CCCCC3)s2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ RAB9A P51151 2/20 0.46
▸ CCNE1 P24864 4/20 0.45
▸ CDK2 P24941 4/20 0.45
▸ CDK5 Q00535 4/20 0.45
▸ LMNA P02545 1/20 0.42
▸ CDK5R1 Q15078 1/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ BTK Q06187 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ FPR3 P25089 1/20 0.38
▸ FPR2 P25090 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ KDM1A O60341 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ OGA O60502 1/20 0.38
▸ LIPG Q9Y5X9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20877417 1.00 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ACCNE1CDK2CDK5
SCHEMBL20877414 0.93 CCNE1 (0.46) SMN1; SMN2RAB9ACCNE1CDK2CDK5
SCHEMBL20877413 0.93 CCNE1 (0.46) SMN1; SMN2RAB9ACCNE1CDK2CDK5
SCHEMBL20883063 0.83 CCNE1 (0.43) CCNE1CDK2CDK5CDK5R1BTK
SCHEMBL20877528 0.83 CCNE1 (0.45) SMN1; SMN2CCNE1CDK2CDK5CDK5R1
SCHEMBL20877527 0.83 CCNE1 (0.45) SMN1; SMN2CCNE1CDK2CDK5CDK5R1
SCHEMBL20883079 0.83 CCNE1 (0.45) SMN1; SMN2CCNE1CDK2CDK5CDK5R1
SCHEMBL24246502 0.82 SMN1; SMN2 (0.61) SMN1; SMN2RAB9ACCNE1CDK2CDK5
SCHEMBL22522925 0.82 GAA (0.40) SMN1; SMN2RAB9ACCNE1CDK2CDK5
SCHEMBL22522948 0.82 SMN1; SMN2 (0.56) SMN1; SMN2RAB9ACCNE1CDK2CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111148743-B Inhibition of ubiquitin-specific peptidase 30 福马治疗有限公司 2023-12-15 — — CN disclosed
EP-3692028-B1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS INC (US) 2023-04-26 — — EP disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 — — US disclosed
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2022-06-16 — — US disclosed
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 FORMA THERAPEUTICS, INC. (US) 2022-02-15 — — US disclosed
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. 2020-10-08 — — US disclosed
EP-3692028-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 Forma Therapeutics, Inc. (US) 2020-08-12 — — EP disclosed
CN-111148743-A Inhibition of ubiquitin-specific peptidase 30 福马治疗有限公司 2020-05-12 — — CN disclosed
WO-2019071073-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 FORMA THERAPEUTICS, INC. (US) 2019-04-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185806-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 SMN1; SMN2 88/4885RAB9A 1612/4885CCNE1 3461/4885
US-11247987-B2 Inhibiting ubiquitin specific peptidase 30 USP30, UCHL1, UCHL3 SMN1; SMN2 181/4885RAB9A 1020/4885CCNE1 2017/4885
US-20200317658-A1 INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 USP30, UCHL1, UCHL3 SMN1; SMN2 88/4885RAB9A 1612/4885CCNE1 3461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback